Compare Agilent Technologies Inc (A) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Raymond James Financial, Inc. — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while Raymond James Financial, Inc. trades at $164.96 (market cap $32.66B). The key difference: Agilent Technologies Inc and Raymond James Financial, Inc. are close in size by market cap, and Raymond James Financial, Inc. pays the higher dividend (1.29%). Which is the better fit depends on your goals.
| A | RJF | |
|---|---|---|
Market Cap | $37.04B | $32.66B |
Sector | Health | Financials |
52-Week High | $157.20 | $176.43 |
52-Week Low | $110.24 | $140.89 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Raymond James Financial (RJF) trades at $167.60, up 3.04% today, near its consensus price target of $168.00. The stock shows a bullish technical trend with strong moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth remains solid, climbing from $10.9B in 2022 to $13.84B in 2025, while net income reached $2.14B. Recent news highlights dividend declarations and record quarterly performance, reinforcing positive sentiment.
Outlook is cautiously optimistic with upside to the high target of $182.00, supported by earnings momentum and analyst coverage. Risks include rising expenses and market volatility. The stock presents a balanced opportunity for growth-oriented investors, though cost management remains a key watchpoint amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
